Covid Flu A/B and RSV 4 in 1 Diagnostic Test

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-15

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the diagnostic performance of an investigational Flu A/B, COVID-19 and RSV test in patients with signs and symptoms of respiratory infection.

The main questions it aims to answer are:

1. What is the sensitivity and specificity of the investigational test compared with an FDA-cleared reference method for detection of Influenza A, Influenza B, , SARS-CoV-2 and respiratory syncytial virus antigen.
2. What is the overall positive and negative percent agreement between the investigational test and the reference method?

Participants will:

1. Provide a respiratory specimen (e.g., nasal or nasopharyngeal swab) for testing with the investigational device.
2. Provide an additional specimen for testing with the FDA-cleared reference method.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza A Influenza B COVID - 19 RSV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational Flu A/B Covid-19 and RSV Diagnostic Test

A diagnostic test in lateral flow cassette format designed to detect Influenza A, Influenza B, SARS-CoV-2 and respiratory syncytial virus from anterior nasal swab specimens.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained prior to study enrollment.
* Male or female aged six (6) months or older.
* Subject is currently exhibiting two or more symptoms associated with COVID-19, influenza or RSV (such as, but not limited to, fever, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea and must present within six (6) days of symptom onset). Subject must still be exhibiting symptoms on the day of sample collection.

Exclusion Criteria

* Subject who is 18 years of age (or the state's legal age of majority) or older and does not understand or is not able and willing to sign the study informed consent.
* Subject has had seasonal influenza and/or the SARS-CoV-2 and/or the RSV vaccine within the past 5 days.
* Subject is not able to tolerate sample collection, or is not willing to contribute the required swab samples for testing or complete the study procedures.
* Subject is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), or peramivir (Rapivab®).
* Subjects currently undergoing treatment and/or within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2.
* Subjects who have taken Evusheld (tixagevimab/cilgavimab) within the last 90 days.
* Subjects who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.
* Subjects who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Interventions

Investigational Flu A/B Covid-19 and RSV Diagnostic Test

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

iHealth Labs inc

Responsible Party

Locations

iHealth Site 006

iHealth Site 021

iHealth Site 017

iHealth Site 007

iHealth Site 008

iHealth Site 026

iHealth Site 011

iHealth Site 013

iHealth Site 004

iHealth Site 005

iHealth Site 019

iHealth Site 014

iHealth Site 028

iHealth Site 009

iHealth Site 012

iHealth Site 027

iHealth Site 010

iHealth Site 024

iHealth Site 015

iHealth Site 016

iHealth Site 020

iHealth Site 003

iHealth Site 002

iHealth Site 018

iHealth Site 023

iHealth Site 025

iHealth Site 001

iHealth Site 022

Countries

Facility Contacts

Liu

Liu

Liu

Liu

Liu

Liu

Liu

Liu

Liu

Other Identifiers

iH018